Skip to main content

Compugen to Divest Bioccelerator Line to Biocceleration

NEW YORK, July 17 - Compugen intends to sell its Bioccelerator product line to Biocceleration next month in exchange for "certain fixed payments" and future royalty rights. 

"By transferring the Bioccelerator product line, we are strengthening Compugen's focus on our two primary commercialization channels: high-end platforms and services that we offer to leading biopharmaceutical companies, and discoveries based on our own internal research," said Mor Amitai, president and CEO of Compugen.


According to Compugen, the Bioccelerator line was designed to accelerate similarity searches in nucleotide and protein databases.

Biocceleration is a bioinformatics company established by a group of private investors, and is headed by Simchon Faigler, who co-founded Compugen in 1993.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.